Liaoning Chengda Biotechnology Co

Liaoning Chengda Biotechnology Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Liaoning Chengda Biotechnology Co (688739.SS) as of Oct 16, 2026 is 24.87 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 40.39 % — a change of -38.42% (lower).

FCF Conversion

24.87 %

YoY

-38.42%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Liaoning Chengda Biotechnology Co is 2025 24.87 % . FCF Conversion Rate (FCF/EBITDA) of Liaoning Chengda Biotechnology Co was 2024 40.39 % . It decreases by -38.42% lower compared to the previous year.

The Liaoning Chengda Biotechnology Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
85.75 CNY
Jan 1, 2019
37.56 CNY
Jan 1, 2020
73.12 CNY
Jan 1, 2021
-0.22 CNY
Jan 1, 2022
4.89 CNY
Jan 1, 2023
26.83 CNY
Jan 1, 2024
40.39 CNY
Jan 1, 2025
24.87 CNY
The Liaoning Chengda Biotechnology Co FCF Conversion history
YEARFCF ConversionYoY
24.87 %-38.42%
40.39 %+50.54%
26.83 %+449.18%
4.89 %-2,313.78%
-0.22 %-100.30%
73.12 %+94.65%
37.56 %-56.19%
85.75 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Liaoning Chengda Biotechnology Co Stock analysis

What does Liaoning Chengda Biotechnology Co do? Liaoning Chengda Biotechnology Co., Ltd. is a prominent entity in the health care sector, specifically operating within the biotechnology industry. Headquartered in Shenyang, located in the Liaoning province of China, the company has established itself as a significant player in the development and commercialization of medical solutions. As of the latest available data, the organization employs a workforce of 1,663 full-time employees, reflecting its substantial operational scale and commitment to research and development activities. The company's primary business focus revolves around the research, development, manufacturing, and sale of vaccines, addressing critical public health needs through innovative biological products. The firm's product portfolio is centered on essential immunizations, including the rabies vaccine for human use and the freeze-dried rabies vaccine for human use. Additionally, the company produces vaccines targeting Japanese encephalitis, specifically offering the inactivated Japanese encephalitis vaccine for human use and the freeze-dried encephalitis inactivated vaccine. These products are marketed under two distinct brand names: Chengda Suda and Chengda Libao, which serve to differentiate the various offerings within the company's lineup. The strategic emphasis on these specific vaccines highlights the company's dedication to combating infectious diseases that pose significant risks to human health. Liaoning Chengda Biotechnology Co., Ltd. entered the public markets through an initial public offering on October 28, 2021, marking a significant milestone in its corporate history and providing it with greater access to capital for future growth and expansion. The company's official online presence can be found at http://www.cdbio.cn, where stakeholders and interested parties can access further information regarding its operations and developments. With its strong foundation in Shenyang and a dedicated team of professionals, the company continues to contribute to the global health care landscape by delivering high-quality vaccine solutions. The combination of its extensive employee base, specialized product range, and public market listing underscores its role as a key contributor to the biotechnology sector in China and beyond. Liaoning Chengda Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Liaoning Chengda Biotechnology Co stock

FCF Conversion Rate (FCF/EBITDA) of Liaoning Chengda Biotechnology Co is 24.87 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Liaoning Chengda Biotechnology Co changed from 40.39 % to 24.87 %, representing a -38.42% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Liaoning Chengda Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Liaoning Chengda Biotechnology Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Liaoning Chengda Biotechnology Co

All Key Metrics — Liaoning Chengda Biotechnology Co